TG Therapeutics Expands BRIUMVI into Treatment-Resistant Schizophrenia with Phase 2 Trial
Event summary
- TG Therapeutics initiated a Phase 2 trial evaluating BRIUMVI in treatment-resistant schizophrenia patients.
- The open-label study will enroll approximately 60 adults aged 18-60 with persistent symptoms despite standard antipsychotic therapy.
- Primary endpoint is a ≥20% reduction in PANSS total score at Week 12, with secondary endpoints including safety and tolerability assessments.
- BRIUMVI's B-cell depletion mechanism targets potential immune system dysfunction in schizophrenia.
The big picture
TG Therapeutics is exploring BRIUMVI's potential beyond its approved multiple sclerosis indication, targeting a significant unmet need in psychiatric care. The trial reflects growing interest in immune system modulation for neuropsychiatric disorders, though commercialization would require navigating complex mental health treatment paradigms and payer dynamics.
What we're watching
- Clinical Efficacy
- Whether B-cell depletion with BRIUMVI can demonstrate meaningful symptom improvement in treatment-resistant schizophrenia patients.
- Regulatory Pathway
- The potential for expanded indications if Phase 2 results are positive, given BRIUMVI's established safety profile.
- Market Opportunity
- The size of the treatment-resistant schizophrenia market and TG Therapeutics' ability to capture share with a novel mechanism.
Related topics